# Tirzepatide Research: Mechanism, SURPASS, SURMOUNT, and Beyond — Cited > Tirzepatide research: dual GIP/GLP-1 receptor pharmacology, SURPASS and SURMOUNT phase 3 trial data, beyond-glycaemia findings, and recent 2024-2025 studies — all cited. Comprehensive literature digest across mechanism, efficacy, safety, and emerging indications — each finding status-tagged and cited. ## The short version Tirzepatide is the first approved drug to activate two incretin receptors — the GIP receptor and the GLP-1 receptor — with a single peptide molecule. 'Incretin' refers to gut-derived hormones released after eating that help the body control blood sugar. By activating both, tirzepatide improves blood sugar control more than drugs targeting only GLP-1, and produces larger weight reductions. The highest quality evidence comes from the SURPASS phase 3 programme (type 2 diabetes) and the SURMOUNT programme (obesity). In SURMOUNT-1 (2539 adults, 72 weeks), the 15 mg dose reduced body weight by an average of nearly 21% — the largest weight reduction recorded for any approved drug in the trial to that point. A head-to-head RCT in people with obesity (SURMOUNT-5) confirmed tirzepatide outperforms semaglutide for weight loss. Tirzepatide has since been approved for obstructive sleep apnea and is under study for liver disease and heart failure. ## Discovery and receptor pharmacology The 2018 discovery paper for LY3298176 (tirzepatide) demonstrated dual GIP and GLP-1 receptor agonism in vitro and showed that chronic administration in mice reduced body weight and food intake significantly more than a selective GLP-1 receptor agonist alone [1]. Phase 1 work in 142 subjects confirmed pharmacokinetics supporting once-weekly subcutaneous dosing, with reduced fasting glucose and body weight versus placebo [1]. In vitro receptor-occupancy and signalling assays (Willard et al., 2020) characterised tirzepatide as an imbalanced dual agonist: it engages the GIP receptor (GIPR) to a greater degree than the GLP-1 receptor (GLP-1R) and shows biased GLP-1R signalling favouring cyclic AMP (cAMP) generation over beta-arrestin recruitment — with weaker GLP-1R internalisation than native GLP-1. Beta-arrestin1 limits the insulin response to native GLP-1 but not to GIP or tirzepatide, explaining part of the potency advantage [2]. Cryo-EM structural studies revealed the near-atomic molecular basis for the dual engagement: key receptor-ligand interactions at both GIPR and GLP-1R binding interfaces, confirming both common and unique features of dual versus single agonism [8]. GIP and GLP-1 receptors are expressed across liver, muscle, adipose tissue, central nervous system, heart, and kidney, enabling tirzepatide's dual engagement to produce cardiometabolic benefits through multiple partly distinct tissue-level pathways [9]. ### Tirzepatide vs semaglutide In SURPASS-2 (open-label 40-week phase 3 RCT, n=1879 T2DM adults), once-weekly tirzepatide at 5, 10, and 15 mg reduced HbA1c by 2.01, 2.24, and 2.30 percentage points versus 1.86 percentage points with semaglutide 1 mg — superior at all doses. Body-weight treatment differences: -1.9, -3.6, and -5.5 kg [3]. In SURMOUNT-5 (open-label 72-week phase 3b RCT, n=751 adults with obesity but not T2DM), tirzepatide at the maximum tolerated dose produced a mean weight change of -20.2% versus -13.7% with semaglutide at maximum tolerated dose (p<0.001), with higher proportions reaching ≥10%, ≥15%, ≥20%, and ≥25% weight loss [5]. An indirect comparison versus oral semaglutide 50 mg (adjusted for sex, ethnicity, and baseline) found weight differences of -4.48% (10 mg) and -5.59% (15 mg) in favour of tirzepatide [13]. ## Glycaemic efficacy — the SURPASS programme SURPASS-1: as monotherapy in adults with T2DM inadequately controlled by diet and exercise, once-weekly tirzepatide produced dose-dependent HbA1c and weight reductions versus placebo [16]. SURPASS-2: superior to semaglutide 1 mg on HbA1c and weight over 40 weeks in 1879 adults with T2DM [3] (detail above). SURPASS-3: tirzepatide superior to insulin degludec on HbA1c and weight, added to metformin (with or without an SGLT2 inhibitor) in T2DM over 52 weeks [17]. SURPASS-5: tirzepatide added to insulin glargine significantly improved glycaemic control and reduced body weight versus placebo in T2DM inadequately controlled on insulin glargine [18]. A JAMA trial confirmed this benefit in a titrated insulin glargine setting [19]. A meta-analysis of 6 RCTs (6,579 participants) across the SURPASS programme confirmed dose-response effects: HbA1c reduction WMD -1.07 percentage points (95% CI -1.44 to -0.56), fasting serum glucose WMD -21.50 mg/dL, and body weight WMD -7.99 kg versus controls, without increased hypoglycaemia risk as monotherapy or add-on [12]. A mechanistic substudy (Thomas et al., 2020) reported that tirzepatide improved markers of beta-cell function (the insulin-producing cells in the pancreas) and insulin sensitivity in people with T2DM [38]. A GIPR-blocking human islet study (El et al., 2023) confirmed that GIPR engagement contributes meaningfully to tirzepatide's insulin secretion in human tissue — and that this contribution differs from mouse islets, where GLP-1R drives more of the effect [11]. A pooled SURPASS analysis in older adults (65+ years) confirmed glycaemic efficacy and safety consistent with the overall programme [14]. ## Tirzepatide weight loss — the SURMOUNT programme SURMOUNT-1: 72-week phase 3 double-blind RCT in 2539 adults with obesity (BMI ≥30 or ≥27 with weight-related complication) and without T2DM. Mean weight change: -15.0% (5 mg), -19.5% (10 mg), -20.9% (15 mg) versus -3.1% placebo. Most common adverse events: gastrointestinal, mostly mild-to-moderate, primarily during dose escalation [4]. An extended follow-up of SURMOUNT-1 (Jastreboff et al., 2025) documented sustained weight reduction and reduced progression from prediabetes to type 2 diabetes over longer observation [39]. SURMOUNT-2: in adults with obesity or overweight and T2DM, tirzepatide (10, 15 mg once weekly) over 72 weeks produced substantial body-weight reductions versus placebo [40]. SURMOUNT-5: tirzepatide -20.2% versus comparator -13.7%, head-to-head in 751 adults with obesity [5] (detail above). SURMOUNT-J (Japan, phase 3 RCT, 225 adults without T2DM): estimated treatment differences in body weight at week 72 of -16.1% (10 mg) and -21.1% (15 mg) versus placebo; ≥5% body-weight reduction achieved by 94% (10 mg) and 96% (15 mg) versus 20% placebo [41]. The tirzepatide weight loss evidence base is among the largest for any approved obesity treatment in the phase 3 literature. ## Tirzepatide results beyond glycaemia and weight SURMOUNT-OSA: in adults with obesity and moderate-to-severe obstructive sleep apnea, tirzepatide (10 or 15 mg) over 52 weeks reduced the apnea-hypopnea index (AHI — the number of breathing interruptions per hour of sleep) by 25.3 events/hour (no PAP device group) and 29.3 events/hour (PAP users) versus approximately 5 events/hour with placebo [34]. This study supported the approval of tirzepatide for moderate-to-severe obstructive sleep apnea in adults with obesity. SUMMIT: in patients with heart failure with preserved ejection fraction (HFpEF — a form of heart failure where the heart's pumping fraction remains normal) and obesity, tirzepatide improved heart-failure outcomes and reduced events versus placebo [35]. SYNERGY-NASH: in adults with metabolic dysfunction-associated steatohepatitis (MASH — a progressive fatty liver disease characterised by inflammation and fibrosis) and moderate-to-severe fibrosis, tirzepatide led to MASH resolution without worsening of fibrosis more often than placebo [36]. Cardiometabolic secondary outcomes: a SURPASS-4 substudy found favourable kidney outcomes (slower eGFR decline, reduced albuminuria) versus insulin glargine in T2DM at high cardiovascular risk [42]. An ambulatory blood-pressure substudy found tirzepatide reduced 24-hour ambulatory systolic blood pressure in adults with BMI ≥27 [43]. SURPASS-CVOT (cardiovascular outcomes trial versus dulaglutide in T2DM with atherosclerotic cardiovascular disease, 2025) provided the cardiovascular outcomes record [44]. ## Recent tirzepatide research 2024-2025 A 2024 pharmacovigilance analysis of FAERS post-market data characterised real-world safety signals for tirzepatide, identifying gastrointestinal events and incorrect dose administration as the most frequent categories [31]. A 2025 meta-analysis specifically examining tirzepatide gastrointestinal events across 13 trials in people with obesity without diabetes quantified the risk versus placebo and examined time-to-onset [20]. Analyses of body composition change during tirzepatide treatment have quantified the lean-mass component of weight lost and evaluated the potential role of resistance exercise [25][26]. A 2024 review of clinical consequences of delayed gastric emptying with incretin therapies addressed perioperative aspiration risk [24]. A 2024 pharmacological signalling study characterised GIP receptor variant-dependent signalling profiles for tirzepatide versus native GIP peptides, confirming biased Gas/cAMP signalling at both GIPR variants (E354 and Q354) [10]. A 2025 pharmacovigilance series on discontinuation and weight regain quantified cardiometabolic parameter worsening following weight regain after stopping tirzepatide [29]. --- Peer-reviewed findings on tirzepatide, summarised and cited — not a prescription, not a clinical recommendation.